June 2023 FDA Recall Tizanidine by Preferred Pharmaceuticals, Inc.
D-0894-2023 - Failed Stability Specifications

This Class II drug recall was voluntarily initiated by Preferred Pharmaceuticals, Inc. on June 26, 2023 for the product Tizanidine. The FDA reported the reason for recall as failed stability specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0894-2023

Reason for Recall
Failed Stability Specifications
Initiated
06-26-2023
Reported
07-12-2023
Quantity
541 Bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Preferred Pharmaceuticals, Inc.
Nationwide within the United States
Tizanidine Hydrochloride Tablet 4mg, packaged in a) 20 count-bottles (NDC 68788-7781-2), b)30-count bottles (NDC: 68788-7781-3), c) 60-count bottles, (NDC: 68788-7781-6), d) 90-count bottles (NDC: 68788-7781-9), e) 120-count bottles (NDC: 68788-7781-8), Rx only, Mfg: Dr. Reddy's Laboratories Limited.

Batch or Lot Expiration Information

Lot# : a) H1621S, Exp: 12/31/2023; b) H2321C, Exp: 12/31/2023; c) H0421B, Exp: 12/31/2023; d) H1721E, H1921T, H3121M, Exp: 12/31/2023, e) H2021G, Exp: 12/31/2023